Tagged with Clinical Trials

CRO Albert Liou discusses the success of the government’s investment in clinical trial infrastructure, which has triggered the rapid growth and advancement of the Korean clinical trial market and spurred innovation in the local life science industry.   What have been some of the main changes for PAREXEL in Korea since…

CRO A senior director for Icon plc discusses Argentina’s strengths and weaknesses as a venue for clinical trials, the role the market plays in a global clinical trial strategy, and Icon’s ambitions for growth in the region.   What are Argentina’s strategic advantages in terms of clinical trial strategy? Argentina in…

clinical trials Dr. Wanda Dobrzanski discusses Argentina’s potential and attractiveness as a clinical research environment and the biggest challenges facing local and global CROs in Argentina.   How has political and popular opposition to clinical trials in Argentina changed over the last five years? Five years ago, the perception of clinical trials…

CRO The opening of the Mexican Social Security Institute (IMSS) to clinical research is a unique opportunity for Mexico to step up on the international scenario for clinical trials. The CEO of Innovare explains how the company is betting on Mexico to conduct clinical R&D and help companies bring innovative drugs to…

stem cell The founder of MEDIPOST, the producer of the only approved allogenic stem cell product in the world, disucsses their development goals for the coming years and the potential for regenerative medicine to revolutionize a variety of healthcare practices. Dr. Yang, to begin, could you please introduce yourself and MEDIPOST to…

clinical trials Auh June-Sun, chairman of Ahngook Pharm, describes the company’s increased focus on R&D and doing US FDA clinical trials. Can you describe your background and introduce yourself to our readers? 2014 was the 55th anniversary of Ahngook’s foundation. I have worked for Ahngook most of my career, although I did…

clinical trials The country manager of a British biopharmaceutical company sheds light on Algeria’s potential for conducting clinical trials and offers his views on the quality of the country’s skilled labour. What is the record of your past fourteen months with AstraZeneca? Since I arrived, I have had two priorities. First, I implemented a new…

clinical trials The general manager of a leading British research-based pharmaceutical company discusses Algeria’s suitability as a destination for pre-clinical and clinical trials and assesses the country’s ability to transition from importer to local producer status Can you please start by briefly introducing GSK in Algeria? GSK activities in Algeria span three…

clinical trials The global CEO of Arianne, who herself happens to be American-Algerian, outlines why, in an era of clinical research globalisation, the country has all the right fundamentals in place to establish itself as a leader in conducting clinical trials and how the Algerian genetic code is well suited for testing Western orientated pharmaceutical…

clinical trials LSK Global PS CEO Young-Jack Lee discusses the influence of global CROs on the quality of Korean research, and outlines his own strategy for competing in the marketplace and growth outside of Korea.   When we met you in 2008, you were positive about the growth of Korean CROs and…

Sanofi Sanofi’s Korean affiliate is the fifth largest recipient of clinical trial investments after the United States, France, Germany and the United Kingdom. Kay Bae, general manager, discusses the benefits of clinical testing in Korea and why ‘open innovation’ is important for progress and development.   You became general manager of…

clinical trials The president of Astellas Korea offers his perspectives on Korea as a base for primary and clinical research, and the company’s recent partnerships in the country.   You became president of Astellas Korea in 2011, following a long career at this affiliate. What were the biggest objectives you had when…